StockData
Hemab Therapeutics Holdings, Inc. logo

Hemab Therapeutics Holdings, Inc. (COAG) company profile

COAGNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 10, 2026
$39.06+0.01 (+0.01%)

Close on Nov 17, 2026Market cap $1.82BP/E –Yield –

About Hemab Therapeutics

Biological Products, (No Diagnostic Substances), SIC 2836

Hemab Therapeutics Holdings, Inc. is listed on Nasdaq under the ticker COAG, in the SEC industry Biological Products, (No Diagnostic Substances). It is incorporated in Delaware and its fiscal year ends on December 31. Reported financials on StockData start in fiscal 2025.

Company profile

Company

Legal name
Hemab Therapeutics Holdings, Inc.
Headquarters
Cambridge, MA
Address
101 Main Street, Suite 1220 02142
Phone
(452) 138-7627
Website
hemab.com
Industry
Biological Products, (No Diagnostic Substances)
Incorporated in
Delaware
Fiscal year ends
December 31

Stock & identifiers

Ticker
COAG
Exchange
Nasdaq
IPO date
May 1, 2026
Shares outstanding
47M, Jul 31, 2026
Filer category
<br>Emerging growth company
SEC CIK
2114044
CUSIP
423494103
ISIN
US4234941031
FIGI
BBG021LKFW00
Share class FIGI
BBG021LKFWY3
EIN
41-4241952

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Benny SorensenSee Remarks, Director–
Catherine MadiganChief Medical Officer–
Mads Nikolaj Behrndt-EriksenSee Remarks36,520
Ananthram Sreenivasa MurthyChief Operating Officer–
Keli WalbertDirector–
RA Capital Nexus Fund IV, L.P.Director–
RA Capital Nexus Fund II, L.P.Director–
John MaraganoreDirector17,974
Linda BainDirector–
Laura TadvalkarDirector–
Akshay VaishnawDirector–

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
May 1, 2026
Offer price
$18.00
Securities offered
16,750,000
Gross proceeds
$301.50M
Exchange
Nasdaq
First trading day
May 1, 2026
First-day close
$34.00+88.9%
Lock-up ends (est.)
Oct 28, 2026

“The initial public offering price per share is $18.00.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Corporate history

Events identified from SEC filings

See a number that looks wrong?